A PYMNTS Company

UK: CMA deepens Illumina-Pacific Biosciences probe

 |  June 27, 2019

Britain’s competition watchdog announced on Thursday, June 27, it would launch an in-depth investigation into the planned US$1.2 billion merger between gene sequencing company Illumina and smaller rival Pacific Biosciences of California.

The Competition and Markets Authority (CMA) stated it would refer the merger to a second phase investigation after the companies refused to address concerns the watchdog had raised last week.

The CMA’s initial⁠—or first phase—investigation had raised concerns about the deal’s impact on the supply of specialist DNA sequencing systems in the UK.

Full Content: Reuters

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.